Business
OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026
OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026
About this update from Ose Immunotherapeutics Sa
Ose Immunotherapeutics Sa has released a press release. View Attachment
View stock analysis, news, and events for Ose Immunotherapeutics Sa
More from Ose Immunotherapeutics Sa
OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for...
September 9, 2026
OSE Immunotherapeutics se félicite de l’inclusion du premier patient traité par Veloxis dans l’étude de phase 2 RENGEVITY-201 évaluant le...
September 8, 2026